Nam, could you just tell us about the shift that's taking place right now in the global market for for weight loss drugs. >> So, I mean, we're we're going really from a few years where Novon Nordisk couldn't make enough semiglutide to supply the market um in the US, let alone in the rest of the world. um to a time when um in a growing number of countries there will be a lot of generic competitors on the market and people will suddenly have access that they never had before to super powerful obesity medicine ...

Core Insights - Novo Nordisk has launched the first GLP-1 pill for weight loss in the U.S., marking a significant advancement in obesity treatment [1] Group 1: Product Launch - The new obesity medicine from Novo Nordisk is now available in pill form, expanding treatment options for patients [1] - This launch represents a major milestone as it is the first oral GLP-1 medication approved for weight loss in the U.S. [1] Group 2: Market Impact - The introduction of the pill is expected to enhance accessibility for patients who may prefer oral medications over injections [1] - This development could potentially increase the market share of Novo Nordisk in the obesity treatment sector [1]